ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical is attractive because its consumables-heavy, U.S.-focused infusion franchise generates recurring demand in a structurally defensive market, while recent 2Q results showed record Consumables and Infusion Systems sales, revenue of $548M, adjusted EBITDA of $110M, and adjusted EPS of $2.37, all ahead of Street estimates. The company’s momentum is also being reinforced by operational execution, with gross margin at 41.0%, adjusted EBITDA margin at 20.1%, guidance raised to $415M-$435M of EBITDA and $8.60-$9.00 of EPS, and leverage cut to 2.3x after $50M of debt paydown. Additional upside comes from competitive share gains, the Medfusion 5000 FDA resubmission expected by the end of the year, and a path toward stronger free cash flow as integration and remediation costs step down.

ICU Medical is viewed negatively because the bear case assumes revenue growth slows to the low-single digits and operating margin improvement remains limited, which would leave earnings below consensus expectations. Pressure on gross margins from inflation and tariffs, weaker-than-expected pricing on GPO/IDN contract renewals, and regulatory setbacks such as product recalls, FDA warning letters, or delayed clearances could further constrain profitability. Even in this scenario, the valuation is only supported at roughly 12x the 2027E adjusted EPS estimate, implying that the market may be overestimating the company’s ability to translate its large installed base and broad product portfolio into stronger margin expansion.